Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Highlights from WCLC 2019

Written by | 21 Oct 2019

The IASLC WCLC meeting, held in Barcelona this year, covered many interesting topics and reported data from clinical trials relevant to the management of lung cancer. In the… read more.

WCLC 2018: Variety of approaches can work in oligometastatic disease

Written by | 17 Oct 2018

Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.

WCLC 2018: Lung cancer stigma is detrimental to patient care

Written by | 17 Oct 2018

Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients’ care.

WCLC 2018: Importance of QOL outcome measures in clinical trials

Written by | 17 Oct 2018

WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.

WCLC 2018: Accessibility & quality of life: a patient focus at WCLC

Written by | 17 Oct 2018

Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said… read more.

WCLC 2018: PACIFIC: durvalumab results impressive, but not without questions

Written by | 17 Oct 2018

Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the… read more.

WCLC 2018: Early ALTA-1L data encouraging for brigatinib

Written by | 17 Oct 2018

The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with… read more.

WCLC 2018: Success of combined screening and smoking cessation pilots

Written by | 17 Oct 2018

Professor Gail Darling (WCLC co-President, Toronto, Canada) discusses the success of combined screening and smoking cessation pilot in Ontario.

WCLC 2018: Do we have a UK-wide screening programme that is ready to implement?

Written by | 17 Oct 2018

Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) and Professor David Baldwin (Nottingham, UK) detail current UK pilots and a screening protocol that is currently going through the NHS England… read more.

WCLC 2018: NELSON – CT screening saves lives

Written by | 17 Oct 2018

A randomised, controlled screening trial for lung cancer involving almost 16,000 people in the Netherlands and Belgium found that CT screening produced a 26% reduction in lung cancer… read more.

WCLC 2018: Highlights

Written by | 17 Oct 2018

The IASLC 19th World Conference on Lung Cancer (WCLC) was full of highlights, including 3 plenary abstracts being presented in the New England Journal of Medicine and involvement from… read more.

ASCO 2012 Report – Afatinib delays tumour progression in advanced NSCLC

Written by | 20 Nov 2012

by Marybeth Burke – Afatinib, an irreversible ErbB-family blocker, delays progression of advanced lung cancer in patients with epidermal growth factor receptor (EGFR) mutations compared with standard chemotherapy,

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.